Trader Hub

Author: traderhub8   |   Latest post: Tue, 28 Jan 2020, 9:55 AM


Singapore Exchange Limited – Record Derivatives Performance Cushions Equities Softness

Author:   |    Publish date:

  • 4Q19 net profit up 24% YoY, 7.6% above our forecast.
  • Derivatives volume surged 33% YoY, driven by FTSE China A50 futures, MSCI Taiwan and iron ore derivatives contracts.
  • SDAV fell 14% YoY as investors adopt a cautious stance in face of slowing economic growth.
  • Full dividend per share of 30 cents fell short of our FY19 DPS target of 31.5 cents.
  • We maintain ACCUMULATE at an unchanged TP of S$8.09. We peg our TP to 21x P/E, 1 SD below SGX’s 5-year mean.

The Positives

+ 4Q19 derivatives volume rose 33% YoY. Record derivatives volume was driven by China A50 index futures which grew 18% YoY and accounted for 37% of total derivatives volume. DDAV improved 33% YoY/ 5% QoQ as we continue to see higher trading volumes across key equity indices, FX futures and commodities contracts due to growth in passive investing and greater hedging needs against market volatility. Derivatives contributed 52% to total revenue. Average fee per contract increased from $1.06 to $1.09 due to lower contribution from market makers. We expect market volatility to be favourable for derivatives volume. But due to potential competition from Hong Kong Exchange’s launch of China A50 index futures, we forecast a relatively unchanged DDAV for FY20-21E of 1,113k and 1,205k respectively.

+ Higher collateral management income. The strong growth was the result of higher margin balances on the back of record open interest due to strong institutional demand of SGX’s derivatives contracts for portfolio risk management. Collateral management, license and other revenue grew 76.5% to $48mn in 4Q.

+ Operating expenses of $449mn hit the lower end of $445-455mn FY19e guidance. We expect operating expense to be higher in 2020 due to three factors; increase headcount, larger depreciation expenses from new systems launched in FY19 and higher royalties and processing fees due to higher derivatives volume expected in 2020. Management guided FY20 operating expenses to be between $465-475mn and technology-related CAPEX to be between $45-50mn.


The Negatives

– Equities softness persists. Equities revenue contracted 17% due to a 14% decrease in SDAV to $1.1bn. Average clearing fees declined from 2.72 bps to 2.66 due to higher participation from market makers. 4Q19 SDAV exceeded our estimates by 7% due to better than expected impact on equities from the stabilisation in global markets. However, due to continued uncertainty in markets, we conservatively maintain our SDAV for FY20-21e at $1.02bn and $1.01bn respectively.

Decent dividend payout. Full-year DPS was $0.30 per share, 5% lower than our expectations. This puts full-year dividend payout ratio at 82% (FY18: 88%). We forecast FY20 DPS of $0.315, reflecting an 81% payout ratio.


Other Updates

SGX-IISL arbitration

SGX is optimistic that the joint proposal submitted by NSE and SGX will receive support from regulatory authorities. No timeline was announced and we await further updates.


Investment Actions

We maintain ACCUMULATE at an unchanged TP of S$8.09. We peg our TP to 21x P/E, 1 SD below SGX’s 5-year mean. At a closing price of $7.92 on 31 July 2019 and based on 32 cents dividend payout, the return is 6.1%. SGX is enjoying structural growth in the derivatives business as it captures global flows into Asian equities, commodities and currencies.

Source: Phillip Capital Research - 1 Aug 2019

Share this
Labels: SGX

Related Stocks

Chart Stock Name Last Change Volume 
SGX 8.73 -0.01 (0.11%) 2,782 

  Be the first to like this.


185  96  165  657 

Top 10 Active Counters
 Medtecs Intl 0.196+0.024 
 Healthway Med 0.044-0.002 
 UG Healthcare 0.375+0.125 
 AsiaMedic 0.0170.00 
 Golden Agri-Res 0.22-0.005 
 Genting Sing 0.87-0.005 
 Rex Intl 0.174+0.006 
 Thomson Medical 0.0630.00 
 MarcoPolo Marine 0.023+0.002 
 Ntegrator Intl 0.012+0.001 
Partners & Brokers